Table 3

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Rio Mamore Hantavirus Endemicity, Peruvian Amazon, 2020

Marta Piche-Ovares, Maria Paquita García, Andres Moreira-Soto, Maribel Dana Figueroa-Romero, Nancy Susy Merino-Sarmiento, Adolfo Ismael Marcelo-Ñique, Edward Málaga-Trillo, Dora Esther Valencia Manosalva, Miladi Gatty-Nogueira, César Augusto Cabezas Sanchez, and Jan Felix Drexler

Author affiliation: Charité-Universitätsmedizin Berlin, Berlin, Germany (M. Piche-Ovares, A. Moreira-Soto, J.F. Drexler); Instituto Nacional de Salud, Lima, Peru (M. Paquita García, M.D. Figueroa-Romero, N.S. Merino-Sarmiento, A.I. Marcelo-Ñique, C.A. Cabezas Sanchez); Universidad Nacional, Heredia, Costa Rica (A. Moreira-Soto); Universidad Peruana Cayetano, Lima (E. Málaga-Trillo); Laboratorio de Referencia Regional de Salud Pública, Lambayeque, Peru (D.E. Valencia Manosalva); Laboratorio de Referencia Regional de Salud Pública, Loreto, Peru (M. Gatty-Nogueira); German Centre for Infection Research, Berlin, Germany (J.F. Drexler)

Main Article

Hantavirus IgG-positive serum samples from Loreto, Lambayeque, and Lima, Peru, 2020*

Sample	Place	Patient age, y/sex	Nationality	Month	IgG ELISA ratio†	IFA result	Interpretation
1788	Lambayeque	13/M	Peruvian	Feb	1.42	SNV, 1.0 × 10²; ANDV/PUUV, 1.0 × 10¹	SNV-like
1818	Lambayeque	6/M	Peruvian	Aug	2.15	Negative	Negative
1835	Lambayeque	29/F	Peruvian	Nov	1.15	Negative	Negative
1866	Lambayeque	60/M	Peruvian	Feb	1.76	Negative	Negative
1882	Lambayeque	20/F	Foreign	Mar	2.24	SNV 1.0 × 10³	SNV-like
1945	Lambayeque	4/F	Foreign	Jan	1.52	Negative	Negative
2738	Lambayeque	15/F	Peruvian	Mar	1.35	Negative	Negative
2740	Lambayeque	84/M	Peruvian	Mar	1.77	Negative	Negative
2003	Lima	48/F	Peruvian	Jan	1.69	SNV 1.0 × 10¹	SNV-like
2069	Lima	19/M	Peruvian	Feb	1.95	SNV, 1.0 × 10³; ANDV, 1.0 × 10²; HTNV/SAAV/DOBV, 1.0 × 10¹	SNV-like
2139	Lima	2/M	Foreign	Mar	1.20	Negative	Negative
2167	Lima	30/M	Peruvian	Jan	2.80	ANDV/SNV, 1.0 × 10³	ANDV/SNV-like
3136	Loreto	6/F	Peruvian	Jan	1.64	ANDV, 1.0 × 10¹	ANDV-like
3249	Loreto	5/M	Peruvian	Jan	1.16	DOBV/SAAV, 1.0 × 10¹	DOBV/SAAV-like
3260	Loreto	5/M	Peruvian	Jan	1.46	ANDV/SNV, 1.0 × 10⁴	ANDV/SNV-like
3317	Loreto	43/M	Peruvian	Jan	1.17	HTNV/DOBV, 1.0 × 10¹	HTNV/DOBV-like
3361	Loreto	22/M	Peruvian	Sep	2.31	ANDV/SNV, 1.0 × 10²	ANDV/SNV-like
3404	Loreto	16/M	Peruvian	Sep	1.12	SNV, 2.5 × 10³; ANDV, 1.0 × 10²; PUUV, 1.0 × 10¹	SNV-like
3562	Loreto	<1/F	Peruvian	Mar	1.96	Negative	Negative
3615	Loreto	16/M	Peruvian	Apr	1.67	SNV, 1.0 × 10³; ANDV/HTNV/DOBV, 1.0 × 10¹	SNV-like
3937	Loreto	<1/M	Peruvian	Mar	5.30	Negative	Negative
4524	Loreto	26/F	Peruvian	Dec	3.16	ANDV/SNV, 1.0 × 10⁴; HTNV/PUUV/SEOV/DOBV, 1.0 × 10¹	ANDV/SNV-like
4591	Loreto	71/M	Peruvian	Jan	1.69	SNV 2.5 × 10³; ANDV 1.0 × 10²; PUUV 1.0 × 10¹	SNV-like

*Boldface indicates positive results (ratio >1.1). ANDV, Andes virus; DOBV, Dobrava virus; HTNV, Hantaan virus; IFA, immunofluorescence assay; PUUV, Puumala virus; SAAV, Saaremaa virus; SEOV, Seoul virus; SNV, Sin Nombre virus.

Main Article

Page created: October 25, 2024

Page updated: November 13, 2024

Page reviewed: November 13, 2024

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.